# ASpirin for Patients With SEPsis and SeptIc Shock

> **NCT01784159** · PHASE2 · TERMINATED · sponsor: **Federal University of São Paulo** · enrollment: 167 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT01784159
- **Lead sponsor:** Federal University of São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-27
- **Primary completion:** 2022-12-15
- **Final completion:** 2023-01-05
- **Target enrollment:** 167 (ACTUAL)
- **Why stopped:** Terminated: The study was stopped prematurely and will not be resumed due to the higher number of bleeding cases in the intervention group, as recomended by the Data Safety Monitoring Board on February 7, 2023.
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01784159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01784159, "ASpirin for Patients With SEPsis and SeptIc Shock". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01784159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*